Certa Therapeutics
- Biotech or pharma, therapeutic R&D
A clinical-stage biotechnology company developing innovative precision therapies for the treatment of fibrotic diseases, Certa is addressing an area of significant unmet need that ultimately causes 35% of all deaths globally and represents a $15bn market.
Certa’s pipeline targets a ‘master switch’ of fibrosis, GPR68, with a series of inhibitors tailored for different fibrotic indications. Asengeprast (FT011) is its lead program, being developed as a first-in-class oral therapy for the treatment of systemic sclerosis (scleroderma), and has successfully completed a multi-national, phase II clinical trial.
The FDA has awarded asengeprast (FT011) Orphan Drug Designation and Fast Track for the treatment of Systemic Sclerosis and the company has additional programs in play to address major indications, including chronic kidney disease, diabetic nephropathy, and other chronic fibrotic indications.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}